Mannan-mediated Gene Delivery for Cancer Immunotherapy

Overview

Journal Immunology

Specialty Allergy & Immunology

Date 2007 Mar 3

PMID 17328786

Citations 15

Authors

Choon K Tang

Jodie Lodding

Gabriela Minigo

Dodie S Pouniotis

Magdalena Plebanski

Anja Scholzen

Ian F C McKenzie

Geoffrey A Pietersz

Vasso Apostolopoulos

Affiliations

Soon will be listed here.

Abstract

Recent years have seen a resurgence in interest in the development of efficient non-viral delivery systems for DNA vaccines and gene therapy. We have previously used oxidized and reduced mannan as carriers for protein delivery to antigen-presenting cells by targeting the receptors that bind mannose, resulting in efficient induction of cellular responses. In the present study, oxidized mannan and reduced mannan were used as receptor-mediated gene transfer ligands for cancer immunotherapy. In vivo studies in C57BL/6 mice showed that injection of DNA encoding ovalbumin (OVA) complexed to oxidized or reduced mannan-poly-L-lysine induced CD8 and CD4 T-cell responses as well as antibody responses leading to protection of mice from OVA+ tumours. Both oxidized and reduced mannan delivery was superior to DNA alone or DNA-poly-L-lysine. These studies demonstrate the potential of oxidized and reduced mannan for efficient receptor-mediated gene delivery in vivo, particularly as DNA vaccines for cancer immunotherapy.

Citing Articles

Recent Advances in Biomedical Applications of Mannans and Xylans.

Teli S, Deshmukh K, Khan T, Suvarna V Curr Drug Targets. 2024; 25(4):261-277.

PMID: 38375843 DOI: 10.2174/0113894501285058240203094846.

Dynamic Imine Bonding Facilitates Mannan Release from a Nanofibrous Peptide Hydrogel.

Pogostin B, Saenz G, Cole C, Euliano E, Hartgerink J, McHugh K Bioconjug Chem. 2022; 34(1):193-203.

PMID: 36580277 PMC: 10061233. DOI: 10.1021/acs.bioconjchem.2c00461.

Novel Approaches in the Immunotherapy of Multiple Sclerosis: Cyclization of Myelin Epitope Peptides and Conjugation with Mannan.

Matsoukas J, Ligielli I, Chasapis C, Kelaidonis K, Apostolopoulos V, Mavromoustakos T Brain Sci. 2021; 11(12).

PMID: 34942885 PMC: 8699547. DOI: 10.3390/brainsci11121583.

Nanoparticles as Adjuvants and Nanodelivery Systems for mRNA-Based Vaccines.

M Alfagih I, Aldosari B, Alquadeib B, Almurshedi A, Alfagih M Pharmaceutics. 2021; 13(1).

PMID: 33396817 PMC: 7823281. DOI: 10.3390/pharmaceutics13010045.

The Long Road of Immunotherapeutics against Multiple Sclerosis.

Apostolopoulos V, Rostami A, Matsoukas J Brain Sci. 2020; 10(5).

PMID: 32403377 PMC: 7287601. DOI: 10.3390/brainsci10050288.

References

Sheng K, Pouniotis D, Wright M, Tang C, Lazoura E, Pietersz G . Mannan derivatives induce phenotypic and functional maturation of mouse dendritic cells. Immunology. 2006; 118(3):372-83. PMC: 1782308. DOI: 10.1111/j.1365-2567.2006.02384.x. View

Martinez-Fong D . Synthesis of a non-viral vector for gene transfer via the high-affinity neurotensin receptor. Brain Res Brain Res Protoc. 2000; 6(1-2):13-24. DOI: 10.1016/s1385-299x(00)00032-5. View

Sato Y, Yamauchi N, Takahashi M, Sasaki K, Fukaura J, Neda H . In vivo gene delivery to tumor cells by transferrin-streptavidin-DNA conjugate. FASEB J. 2000; 14(13):2108-18. DOI: 10.1096/fj.99-1052com. View

Cho Y, Kim J, Park K . Polycation gene delivery systems: escape from endosomes to cytosol. J Pharm Pharmacol. 2003; 55(6):721-34. DOI: 10.1211/002235703765951311. View

Perales J, Ferkol T, Beegen H, Ratnoff O, Hanson R . Gene transfer in vivo: sustained expression and regulation of genes introduced into the liver by receptor-targeted uptake. Proc Natl Acad Sci U S A. 1994; 91(9):4086-90. PMC: 43728. DOI: 10.1073/pnas.91.9.4086. View

Apostolopoulos V, Loveland B, Pietersz G, McKenzie I . CTL in mice immunized with human mucin 1 are MHC-restricted. J Immunol. 1995; 155(11):5089-94. View

Apostolopoulos V, Matsoukas J, Plebanski M, Mavromoustakos T . Applications of peptide mimetics in cancer. Curr Med Chem. 2002; 9(4):411-20. DOI: 10.2174/0929867023370969. View

Apostolopoulos V, Yuriev E, Ramsland P, Halton J, Osinski C, Li W . A glycopeptide in complex with MHC class I uses the GalNAc residue as an anchor. Proc Natl Acad Sci U S A. 2003; 100(25):15029-34. PMC: 299892. DOI: 10.1073/pnas.2432220100. View

Zenke M, Steinlein P, Wagner E, Cotten M, Beug H, Birnstiel M . Receptor-mediated endocytosis of transferrin-polycation conjugates: an efficient way to introduce DNA into hematopoietic cells. Proc Natl Acad Sci U S A. 1990; 87(10):3655-9. PMC: 53961. DOI: 10.1073/pnas.87.10.3655. View

10.

Matulis D, Rouzina I, Bloomfield V . Thermodynamics of cationic lipid binding to DNA and DNA condensation: roles of electrostatics and hydrophobicity. J Am Chem Soc. 2002; 124(25):7331-42. DOI: 10.1021/ja0124055. View

11.

Gac S, Coudane J, Boustta M, Domurado M, Vert M . Synthesis, characterisation and in vivo behaviour of a norfloxacin-poly(L-lysine citramide imide) conjugate bearing mannosyl residues. J Drug Target. 2000; 7(5):393-406. View

12.

Schatzlein A . Targeting of Synthetic Gene Delivery Systems. J Biomed Biotechnol. 2003; 2003(2):149-158. PMC: 323958. DOI: 10.1155/S1110724303209116. View

13.

Perales J, Grossmann G, Molas M, Liu G, Ferkol T, Harpst J . Biochemical and functional characterization of DNA complexes capable of targeting genes to hepatocytes via the asialoglycoprotein receptor. J Biol Chem. 1997; 272(11):7398-407. DOI: 10.1074/jbc.272.11.7398. View

14.

Apostolopoulos V, Pietersz G, Tsibanis A, Tsikkinis A, Drakaki H, Loveland B . Pilot phase III immunotherapy study in early-stage breast cancer patients using oxidized mannan-MUC1 [ISRCTN71711835]. Breast Cancer Res. 2006; 8(3):R27. PMC: 1557739. DOI: 10.1186/bcr1505. View

15.

Diebold S, Lehrmann H, Kursa M, Wagner E, Cotten M, Zenke M . Efficient gene delivery into human dendritic cells by adenovirus polyethylenimine and mannose polyethylenimine transfection. Hum Gene Ther. 1999; 10(5):775-86. DOI: 10.1089/10430349950018535. View

16.

Cui Z, Mumper R . Microparticles and nanoparticles as delivery systems for DNA vaccines. Crit Rev Ther Drug Carrier Syst. 2003; 20(2-3):103-37. DOI: 10.1615/critrevtherdrugcarriersyst.v20.i23.10. View

17.

Loveland B, Zhao A, White S, Gan H, Hamilton K, Xing P . Mannan-MUC1-pulsed dendritic cell immunotherapy: a phase I trial in patients with adenocarcinoma. Clin Cancer Res. 2006; 12(3 Pt 1):869-77. DOI: 10.1158/1078-0432.CCR-05-1574. View

18.

Plebanski M, Gilbert S, Schneider J, Hannan C, Layton G, Blanchard T . Protection from Plasmodium berghei infection by priming and boosting T cells to a single class I-restricted epitope with recombinant carriers suitable for human use. Eur J Immunol. 1998; 28(12):4345-55. DOI: 10.1002/(SICI)1521-4141(199812)28:12<4345::AID-IMMU4345>3.0.CO;2-P. View

19.

Barratt G, Tenu J, YAPO A, PETIT J . Preparation and characterisation of liposomes containing mannosylated phospholipids capable of targetting drugs to macrophages. Biochim Biophys Acta. 1986; 862(1):153-64. DOI: 10.1016/0005-2736(86)90479-7. View

20.

Kunath K, von Harpe A, Fischer D, Kissel T . Galactose-PEI-DNA complexes for targeted gene delivery: degree of substitution affects complex size and transfection efficiency. J Control Release. 2003; 88(1):159-72. DOI: 10.1016/s0168-3659(02)00458-3. View